Capital FM reports that Moderna has signed an agreement with Kenya to set up its manufacturing plant, the first on the continent. According toÂ President Uhuru Kenyatta, Kenya is pleased to partner with Moderna in the establishment of the mRNA manufacturing facility, to help prepare the country and sister African states - through the AU- to respond to future health crises and stave off a pandemic in the future. Moderna's investment in Kenya will help advance equitable global vaccine access and is part of the structural developments that will enable Africa to become an engine of sustainable global growth. In its prophylactic vaccines modality, Moderna's mRNA pipeline includes 28 vaccine programmes including vaccines against respiratory viruses, vaccines against latent viruses and vaccines against threats to global public health.